Page 371 - Read Online

Pereira et al. J Cancer Metastasis Treat 2018;4:30 I http://dx.doi.org/10.20517/2394-4722.2018.13 Page 11 of 14

16. Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from
bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165.
17. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM, Schwartz AG, Brown LM, Greenberg RS,
Schoenberg JB, Pottern LM, Hoover RN, Fraumeni JF Jr. Diabetes mellitus, other medical conditions and familial history of cancer as
risk factors for pancreatic cancer. Br J Cancer 1999;80:1830-7.
18. Kamarajah SK, Burns WR, Frankel TL, Cho CS, Nathan H. Validation of the American Joint Commission on Cancer (AJCC) 8th edition
staging system for patients with pancreatic adenocarcinoma: a surveillance, epidemiology and end results (SEER) analysis. Ann Surg
Oncol 2017;24:2023-30.
19. Silvestris N, Longo V, Cellini F, Reni M, Bittoni A, Cataldo I, Partelli S, Falconi M, Scarpa A, Brunetti O, Lorusso V, Santini D,
Morganti A, Valentini V, Cascinu S. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol
2016;98:309-24.
20. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
21. Cancer Facts & Figures 2017. American Cancer Society 2017.
22. McIntyre CA, Winter JM. Diagnostic evaluation and staging of pancreatic ductal adenocarcinoma. Semin Oncol 2015;42:19-27.
23. Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol
2014;20:10740-51.
24. Shaib WL, Ip A, Cardona K, Alese OB, Maithel SK, Kooby D, Landry J, El-Rayes BF. Contemporary management of borderline
resectable and locally advanced unresectable pancreatic cancer. Oncologist 2016;21:178-87.
25. Buanes TA. Role of surgery in pancreatic cancer. World J Gastroenterol 2017;23:3765-70.
26. Kleeff J, Diener MK, Z’Graggen K, Hinz U, Wagner M, Bachmann J, Zehetner J, Müller MW, Friess H, Büchler MW. Distal
pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg 2007;245:573-82.
27. Ho CK, Kleeff J, Friess H, Buchler MW. Complications of pancreatic surgery. HPB (Oxford) 2005;7:99-108.
28. Kim CB, Ahmed S, Hsueh EC. Current surgical management of pancreatic cancer. J Gastrointest Oncol 2011;2:126-35.
29. Bachmann J, Michalski CW, Martignoni ME, Buchler MW, Friess H. Pancreatic resection for pancreatic cancer. HPB (Oxford)
2006;8:346-51.
30. Kircher SM, Krantz SB, Nimeiri HS, Mulcahy MF, Munshi HG, Benson AB 3rd. Therapy of locally advanced pancreatic
adenocarcinoma: unresectable and borderline patients. Expert Rev Anticancer Ther 2011;11:1555-65.
31. Cerqueira NM, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry
2007;13:8507-15.
32. Burris HA 3rd MM, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P,
Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for
patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
33. Kim EJ, Semrad TJ, Bold RJ. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin
Investig Drugs 2015;24:781-94.
34. Scheithauer W. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic
adenocarcinoma: a randomized phase II trial. Ann Oncol 2003;14:97-104.
35. Berlin JD, Adak S, Vaughn DJ, Flinker D, Blaszkowsky L, Harris JE, Benson IIIAB. A phase II study of gemcitabine and 5fluorouracil
in metastatic pancreatic cancer: an eastern cooperative oncology group study (E3296). Oncology 2000;58:215-8.
36. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF. Phase II study of
gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001;92:569-77.
37. Stathopoulos GP. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II
study by the Greek cooperative group for pancreatic cancer. Ann Oncol 2003;14:388-94.
38. Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G, Biasco G. Metastatic pancreatic cancer: Is gemcitabine still
the best standard treatment? (Review). Oncol Rep 2010;23:1183-92.
39. Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, Vokes EE. Gemcitabine plus sorafenib
in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago phase II consortium. Invest New Drugs
2012;30:382-6.
40. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL. Cetuximab, a monoclonal antibody
targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II
trial. J Clin Oncol 2004;22:2610-6.
41. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with
fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: eastern cooperative oncology group trial E2297.
J Clin Oncol 2002;20:3270-5.
42. Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis
J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with
gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer
2006;95:587-92.
43. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-
Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol
2006;24:3946-52.